Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

被引:0
作者
Minas P. Economides
Srdan Verstovsek
Naveen Pemmaraju
机构
[1] The University of Texas School of Health Sciences at Houston,Department of Internal Medicine
[2] The University of Texas MD Anderson Cancer Center,Department of Leukemia
来源
Current Hematologic Malignancy Reports | 2019年 / 14卷
关键词
Ruxolitinib; Myeloproliferative neoplasms; Novel therapies; JAK inhibitors; Novel drugs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:460 / 468
页数:8
相关论文
共 1003 条
[1]  
Dameshek W(1951)Some speculations on the myeloproliferative syndromes Blood 6 372-375
[2]  
Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405
[3]  
Orazi A(2005)Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387-397
[4]  
Hasserjian R(2005)Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054-1061
[5]  
Thiele J(2005)A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144-1148
[6]  
Borowitz MJ(2006)MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 3 e270-2405
[7]  
Le Beau MM(2013)Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med 369 2391-2390
[8]  
Levine RL(2013)Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 369 2379-e133
[9]  
Wadleigh M(2014)Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis Blood 123 e123-807
[10]  
Cools J(2012)A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 799-435